Citation

87 FR 41135

Multiple canonical documents share this first-page citation.

Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability; Correction Monday, July 11, 2022 87 FR 41135
Xellia Pharmaceuticals USA, LLC; Withdrawal of Approval of an Abbreviated New Drug Application for Bacitracin for Injection Monday, July 11, 2022 87 FR 41135